NASDAQ · TECH
Bio-Techne Corporation
Healthcare · Biotechnology
$72.71▲ 0.03% ($0.02)at close
After hours$72.99▲ 0.39%7:56 PM ET
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 21.8% revenue growth a year for 10 years. Our scenarios assume 0.9–4.4%.
That's 9.1× its past 4-year pace.
Value per share
Base case
$18.34
Price used $72.71 is 4.0× this
USD · TTM ending Jun 30, 2026 · Price Oct 29, 8:00 PM UTC
Revenue each value needs
Revenue today $1.2B. The price needs $8.7B by 2036. Base case: $1.4B. At its recent pace: $1.5B. Bear to Bull: $1.3B to $1.9B.
Revenue today $1.2B. The price needs $8.7B by 2036. Base case: $1.4B. At its recent pace: $1.5B. Bear to Bull: $1.3B to $1.9B.
Revenue in 2036
today $1.2B
+$7.3Bmore than the Base case · 6.4×
Value per share · Base case
$18.34
Price $72.71
4.0× this
- 10-yr revenue CAGR
- 1.2%
- Ending operating margin
- 20.7%
- Discount rate
- 10.3%
USD · TTM ending Jun 30, 2026 · Price Oct 29, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 17.24% over the last year. Revenue declined 0.38% in FY2026 versus FY2025. Operating margin moved from 8.38% to 20.73% (FY2026 versus FY2025). Free cash flow grew 2.6% in FY2026 versus FY2025.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 38th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 20.73%. Revenue declined 0.38% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Return analysis
Company profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Market multiples
Stock splits
Every 1 shares became 4
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
12
Buy
14
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 4, 2026
Q1 FY27 · EPS est $0.44 · Revenue est $292.6M
Same quarter, year over year
FY26 Full year 0.0%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q4 combined $1.93 vs $1.93 · 1 of 4 quarters up
Q1
Q2
Q3
Q4
FY total
FY27
—
—
—
—
FY26
FY25
FY24
Fiscal year totals
- FY26
- $1.93
- 0.0%
- FY25
- $1.93
- +8.4%
- FY24
- $1.78
- —
Q4 FY26
Reported Aug 12, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.52
Estimate
$0.52
Year over year
-1.9%
Vs prior quarter
-1.9%
Institutional Sentiment
Bio-Techne Corporation · TECH
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.